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Signal transducer and activator of transcription (STAT) 3 has been considered a 
potential anti-cancer target since its first description as an oncogene in 19991. Since then, two 
STAT3 inhibitors have been brought to clinical trial for the treatment of solid tumors. However, 
the past 14 years of intense basic research have uncovered novel STAT3 functions that could 
affect the outcome of the designed therapeutic approach, or could help designing function-
specific inhibitors.  
STAT3 was originally termed acute phase response factor, for its ability to mediate the 
increased expression of acute phase proteins in liver cells in response to inflammation2. 
Thereafter, many studies have demonstrated constitutive tyrosine phosphorylation (Y-P) of 
STAT3, mediating dimerization, nuclear localization and transcriptional activity and 
correlating with increased expression of its target genes, in a variety of human tumors of both 
solid and liquid origin3. Persistent STAT3 activation mainly occurs downstream of either 
continuous stimulation by cytokines and growth factors, or constitutive activity/expression of 
pro-oncogenic tyrosine kinase molecules such as for example cSrc, and only marginally via 
activating genetic mutations4. Indeed, STAT3 Y-P and transcriptional activity are required for 
tumor transformation downstream of Src and several other oncogenes5, and interfering with 
STAT3 leads to growth arrest and apoptotic cell death in the vast majority of tumor cells 
displaying constitutive activity of this factor6, 7. These observations have prompted the 
development of a number of approaches to inhibit STAT3 transcriptional activity with the goal 
of treating Y-P STAT3 positive cancers.  
However, STAT3 has also been associated to anti-oncogenic functions in thyroid tumors and 
in late stage APCMin intestinal tumors8, 9 highlighting the complexity of its functions.  
 The heterogeneity of STAT3 gene expression signature, in both tumors and tissues of 
different origin, suggests that a core function for STAT3 in tumors has not been identified yet. 
On this regard, important connections between STAT3 activities and cell metabolism have 
recently emerged. First, constitutively active Y-P STAT3 was shown to support a glycolysis-
like state through the transcriptional induction of the hypoxia-responsive factor HIF-1α and the 
down-regulation of mitochondrial activity10. Further implications with the regulation of cell 
metabolism were suggested by the observation that STAT3 can be chronically activated via Y-
P by the HIF-1-induced pyruvate kinase M2 isoform (PKM2), starting a positive feedback loop 
to support cell proliferation and survival11. This switch towards aerobic glycolysis may be 
required for rapid proliferation of cancer cells as well as to drive their plasticity to adapt and 
survive in environments of different oxygen concentrations, thus partially explaining the 
addiction for STAT3 shown by so many biologically different tumors10. 
STAT3 encounters other post-translational modifications such as phosphorylation on 
Serine residue 727 (S-P), which also appears to be involved in the control of metabolic 
processes. Indeed, S-P STAT3 localizes into the mitochondria, where it preserves oxidative 
phosphorylation and opposes the opening of the mitochondrial permeability transition pore, 
thus inhibiting apoptosis12, 13. This function was shown to be required for tumor transformation 
mediated by oncogenic RAS, paradoxically favoring both aerobic glycolysis and ETC 
activity14. STAT3 appears therefore to function as a hub to integrate different oncogenic 
signals, via both mitochondrial and nuclear activities15 (Fig. 1). An outstanding question 
remains how STAT3 would exert its activity within the mitochondrion, since its very low 
abundance in this organelle challenges the proposed mechanism based on the interaction with 
specific electron transport complexes of the mitochondrial inner membrane16. 
STAT3 chemical or genetic inhibition accelerates the autophagic flux due to an 
inhibitory interaction of the STAT3 SH2 domain with the cytoplasmic PKR kinase17. 
Interfering with either the STAT3 cytoplasmic localization, through constitutive or acute Y-P 
activation, or with its SH2 domain, using specific drugs such as STATTIC or S3I, may in 
principle increase the pool of free PKR and basal autophagy (Fig. 1). This relatively 
straightforward mechanism, however, fails to explain why also inhibitors that indirectly 
prevent STAT3 phosphorylation, such as the Jak kinase inhibitor WP1066, were also able to 
increase basal autophagy in the absence of constitutively active STAT3 Y-P, suggesting more 
complicated interplays between the different forms of STAT3. 
The novel nuclear, mitochondrial and cytoplasmic functions of STAT3 in the regulation 
of cellular metabolism are clearly finely tuned in physiological conditions. This balance is 
likely disrupted in different pathologies, making the dissection of the single activities and the 
expected outcome of drug treatments more complex.  
The two inhibitors under clinical trial are both based on interfering with STAT3 
transcriptional activity. The first drug is a decoy oligonucleotide recently assessed in phase 0 
trials for the treatment of head and neck cancers18. The second drug (OPB-31121) is a small 
molecule currently in Phase 1 for advanced solid tumors, which down-regulates the expression 
of the upstream kinase JAK2 and of the signaling receptor gp130, thus indirectly decreasing 
the rate of STAT3 Y-P19.  
We and others have shown that the chronic transcriptional activity of STAT3 is able to 
act as a first hit in the process of malignant transformation20. Moreover, the level of circulating 
IL-6, one of the best characterized STAT3-activating factors, increases with age, thus 
supporting a possible age-dependent chronic STAT3 tyrosine-activation21.  Since aging is the 
single factor with the highest impact on cancer initiation, interfering with STAT3 
transcriptional activity may be useful as a prophylactic therapy to reduce the rate of cellular 
transformation. Systemic prophylactic STAT3 blockade by means of specific inhibitors would 
presumably be too toxic, due to continued inhibition of its physiological functions, but effective 
results might be achieved by chronic anti-inflammatory treatments.  
Once the tumor is already established, however, inhibiting STAT3 transcriptional 
activity will eventually increase the pool of monomeric protein in the cancer cells. We have 
shown that chemically interfering with the constitutively activated form of STAT3 leads to a 
‘counter-switch’ to oxidative phosphorylation10. On one side, this effect will initially slow 
down proliferation and adaptation to a hypoxic environment. On the other side, the increased 
abundance of monomeric STAT3 may increase its availability for mitochondrial localization, 
which might eventually lead to enhanced ATP production and glycolysis rate, as previously 
described12. On the other hand, constitutively activated STAT3 might indirectly favor 
autophagy simply by increasing the pool of active PKR in the cytoplasm; accordingly, many 
STAT3 inhibitors, including those under clinical trial like the decoy and OPB-31121, lead to 
an increased pool of cytoplasmic STAT3 able to interact with PKR, and should therefore 
decrease autophagy, while inhibitors blocking the SH2 domain should enhance it. As 
autophagy can have both beneficial and pathogenic effects in cancer22, the end results of such 
treatments may vary according to the tumor type and stage. STAT3 contrasting functions in 
tumorigenesis, where this factor can sometimes play oncosuppressive functions, may very well 
relate to different metabolic needs of specific tumors.  
Despite the concept of STAT3 as an oncogene gaining strength during these years, the 
new twists discussed here suggest that its novel metabolic functions, both transcriptional-
dependent and –independent, need to be kept in strong consideration for the development of 
new therapeutic strategies. First, combinatorial therapies based on inhibiting STAT3 
transcriptional activity and interfering with cell metabolism might be redundant; second, 
therapies based on inhibiting STAT3 transcriptional activity might have different and opposite 
outcomes depending on the oncogenic signals activated; third, since cancer cells might rely on 
STAT3 also independently from its dimerization, its tyrosine phosphorylation might not be a 
suitable diagnostic for STAT3-dependent cancer.  
These considerations underline the need to deepen our knowledge of the role played by 
the different STAT3 forms (Y-P versus S-P, nuclear versus cytoplasmic or mitochondrial, 
dimeric versus monomeric) and their relative distribution in different kinds of tumors and 
downstream of different activated oncogenic pathways. In turn this new knowledge will help 
defining specific effective inhibition strategies as well as establishing guidelines to assess 
treatment outcome. 
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Figure Legend  
Multiple metabolic roles of STAT3 according to stimulus, post-transcriptional 
modification and subcellular localization.  In both normal and tumor cells STAT3 can be 
found in the mitochondrial matrix (mSTAT3), in the nucleus (nSTAT3) and in the cytoplasm 
(cSTAT3), depending on specific post-transcriptional modifications (i.e. Y-P, S-P or none) that 
are triggered by different upstream stimuli. (a) P-S mSTAT3, induced among others by RAS 
oncogenic signals and the activation of MAP kinases, can improve cell survival by enhancing 
both oxidative phosphorylation and aerobic glycolysis, and protects cells from apoptosis by 
inhibiting the opening of the mitochondrial permeability transition pore (MPTP) via its 
interactions with the pore component Cyclophylin D (CypD). (b) In contrast, many oncogenic 
signals including inflammatory cytokines, growth factors and oncogenes mainly induce P-Y 
nSTAT3, which mediates the upregulation of the oxygen sensor Hif-1 thus leading to 
increased glycolysis and metabolic advantages for proliferating cells. Moreover, STAT3 can 
be chronically activated by the HIF-1-induced PKM2, thus initiating a positive feedback loop 
to support cell proliferation and protection from apoptosis and senescence. On the other hand, 
nSTAT3 decreases mitochondrial activity in an Hif-1-independent manner by down-
regulating a significant number of mRNAs encoding for protein components of the ETC 
complexes, thus leading to reduce mitochondrial respiration, ROS production and apoptosis. 
(c) Finally, cSTAT3 has been recently shown to inhibit autophagy by interacting via its SH2 
domain with the cytoplasmic Protein Kinase R (PKR). 
Adenine nucleotide translocator (ANT); Voltage-dependent anion channel (VDAC).  
 
 

